| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
B Signal Pathway1
Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders/NIH, Bethesda, Maryland 20892 [G. D., E. L., Z. C., T. I. C., C. V. W.], and National Cancer Institute, Division of Clinical Sciences and Microarray Facility, Advanced Technology Center, Gaithersburg, Maryland 20887 [L. G., E. T. L.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B signal pathway. The NF-B-inducible cytokine Gro-1 was recently shown to promote tumor growth, metastasis, and angiogenesis of squamous cell carcinomas in vivo (Loukinova et al., Oncogene, 19: 3477–3486, 2000). The results demonstrate that early response genes related to NF-B contribute to metastatic tumor progression. Comparison of cell lines and tumor tissue revealed a concordance of 
50% by array, and 70% for Northern-confirmed, metastasis-related genes. Functional genomic approaches comparing expression among cell lines and tumor tissue may promote a better understanding of the genes expressed by malignant and host cells during tumor progression and metastasis. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B, AP-1, and signal transducer and activator of transcription-3, are constitutively activated in SCC (8, 9, 10)
. Activation of NF-B, AP-1, and signal transducer and activator of transcription-3 have been found to contribute to tumor cell transformation, proliferation, migration, survival, and resistance to chemo- and radiation therapy in a variety of different cancers (9, 10, 11, 12, 13, 14, 15, 16)
. However, there has been limited characterization of the global changes in expression of genes and their relationship to activation of specific signal pathways during transformation and metastasis of SCC. Such studies have been limited by the lack of well-defined models of metastasis and technical obstacles to the comparative analysis of large numbers of genes in multiple samples.
To recapitulate the stages of transformation and metastatic tumor progression of SCC, we have developed a syngeneic model of SCC that includes the spontaneously transformed BALB/c keratinocyte line Pam 212 (17)
, and rare lymph node and lung metastases (LY and LU) of Pam 212 (18)
. The metastatic Pam LY and Pam LU cell lines were found to form tumors and metastases at a higher rate than the parental Pam 212 tumor line in vivo (18)
in association with increased expression of a repertoire of proinflammatory and proangiogenic factors (19
, 20)
that are regulated by transcription factor NF-B (21)
. The development of mRNA DD and, more recently, cDNA microarray technology has made it feasible to analyze the expression of large numbers of genes and their potential relationship to activation of signal pathways such as NF-B during the stages of transformation and metastasis.
In the present study, we used mRNA DD to detect global differences and cDNA microarrays enriched to detect cancer-associated genes to examine stable differences in mRNA expression between primary keratinocytes, transformed Pam 212 squamous carcinoma cells, and metastases of Pam 212. Microarray analysis was also used to compare mRNA from tumor cells grown in vitro and in vivo to obtain an estimate of differences in mRNA between cell lines and heterogeneous tumor tissue. cDNAs differentially expressed between the nontransformed and transformed cell lines and between the transformed and metastatic variant cell lines were identified, including genes with functional activities involved in growth, resistance and apoptosis, inflammation and angiogenesis, and signal transduction. Microarray analysis identified a cluster of genes showing increased expression in metastatic lines, 10 of which were related to the NF-B pathway. The results of genomic analysis along with recent functional analysis of several candidate genes in this murine SCC model provide evidence for the importance of the expression of NF-B-related genes in the metastatic tumor progression of SCC. Comparison of cell lines and tumor tissue revealed a concordance of 50% by array, and 70% for Northern-confirmed, metastasis-related genes. Functional genomic approaches comparing expression among cell lines and tumor tissue may promote a better understanding of genes expressed by malignant and host cells during tumor progression and metastasis.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
1 cm in diameter, and tumors were dissected free of skin, underlying tissue, and capsule and snap frozen and stored at -80°C.
RNA Isolation, mRNA Differential Display, and Northern Blot Analysis.
Total RNA was isolated from cultured primary keratinocytes, Pam 212, LY-1, LY-2, LY-8, and LU-1 cells using Trizol reagent (Life Technologies, Inc., Gaithersburg, MD). DD was performed with RNAimage kits (GenHunter Co., Brookline, MA) following the manufacturer’s instructions, as described previously (19)
. Anchor primers H-T11C and H-T11A were used for reverse transcription of mRNAs, and the resulting cDNAs were amplified by PCR using these anchor primers and random primer sets H-AP1–8 and H-AP17–32. To confirm the results of DD, Northern blotting analysis was performed using 20 µg of total RNA from the above cell lines with 32P-labeled cDNA probes from DD, as described (19)
. Each blot was then stripped and rehybridized with a glyceraldehyde-3-phosphate dehydrogenase probe to confirm equal loading. After sequencing of cloned DD products using the Dye Terminator ABI PRISM Kit (Perkin-Elmer, Foster City, CA), the alignment of insert sequences was performed with MacDNASIS (Hitachi Software Engineering America, Ltd., San Bruno, CA), and the BLAST program was used for the homology search of GenBank.
cDNA Arrays, Probes, Hybridization, and Scanning.
Poly(A)+ RNA or total RNA was isolated from primary cultured murine keratinocyte, PAM 212, LY-1, and LY-2 cells and tumors of PAM 212, LY-1, and LY-2 using the FastTrack mRNA isolation kit (Invitrogen, Carlsbad, CA) or Trizol reagent, respectively (Life Technologies, Inc.). mRNA from primary mouse keratinocytes, tumor line Pam 212, and metastatic lines LY-1 and LY-2 were used to generate Cy3- or Cy5-labeled first-strand cDNA by reverse transcription, and the cDNA products were used to hybridize array slides. To examine similarities and differences between cultured cells and tumors arising from these lines in vivo, mRNA was also isolated from PAM 212, metastatic LY-1, and LY-2 tumors grown in BALB/c mice and labeled for array analysis. mRNA from Pam 212 cells was labeled with Cy5 dye and paired with the rest of samples that were labeled with Cy3 dye to allow a direct comparison between primary keratinocytes and PAM 212 tumor line or PAM 212 line and metastatic lines. To make fluorescence-labeled cDNA targets by reverse transcription, 1–2 µg of poly(A)+ RNA or 50–100 µg of total RNA was incubated in a cocktail containing Cy3 or Cy5-dUTP (Amersham Pharmacia Biotech Inc., Piscataway, NJ) and SuperScript II RT (Life Technologies, Inc.). Labeled targets were purified using a Microcon column (Millipore, Bedford, MA). The appropriate Cy3 and Cy5 targets were combined, along with 2 µl (20 µg) of mouse COT-1 DNA, 1 µl (8–10 µg) of poly(A), 2.6 µl of 20x SSC, and 0.45 µl of 10% SDS in a final volume of 15 µl. After denaturation, labeled targets were added to processed National Cancer Institute mouse array slides which were then placed in hybridization chambers and incubated overnight (10–16 h) at 65°C. The next day, slides were washed for 1 min in 1x SSC, for 1 min in 0.2x SSC, for 10 s in 0.05x SSC, then spin dried. Fluorescence images were captured using a Genepix 4000 (Axon Instruments, Inc., Foster City, CA).
Statistical and Cluster Analysis of Array Data.
Both image and signal intensity data were stored in a database supported by the Center for Information Technology of NIH. Cy3:Cy5 intensity ratios from each gene were calculated and subsequently normalized to ratios of overall signal intensity from the corresponding channel in each hybridization. In all of the data sets included for the data analysis, ratios of overall signal intensity ranged from 0.7 to 1.25. The ratio distribution extracted from microarray images exhibited a normal distribution, constant coefficient-of-variation, and sufficient positivity (we used 3-fold above background as the intensity cutoff in current experiments), satisfying the statistical conditions necessary to determine the significance of ratio measurements by the confidence interval generated using Array Suite software developed at the National Human Genome Research Institute (Bethesda, MD; Ref. 22
). Under our experimental conditions, a 99% confidence interval defined ratios of 2 and larger or 0.5 and smaller as indicators of significantly different gene expression levels between two samples hybridized to the same array spot. These ratios were designated as positives. A set of 287 cDNAs was extracted from the database by filtering cDNAs with at least two positive ratios among 10 hybridizations.
For clustering analysis, we used Cluster and Treeview array data clustering and visualization software developed at Stanford University (23) . Log2-converted expression data from the set of 287 cDNAs measured across 10 hybridizations were subjected to one-dimensional hierarchical clustering, and we used this 287 x 10 (cDNA versus specimens) expression table in Cluster to generate gene dendrograms based on the pair-wise calculation of the Pearson correlation coefficient of normalized fluorescence ratios as measures of similarity and average linkage clustering. The reordered table from Cluster was imported into Treeview and displayed by a graded color scheme, representing ratios for each cell line in the expression table.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. We compared mRNA expression between primary keratinocytes, the spontaneously transformed squamous carcinoma line PAM 212, and PAM 212-derived LY and LU cell lines. The PAM 212 line used for these studies is tumorigenic and forms SCCs, whereas the PAM LY and LU cell lines reisolated from rare metastases exhibit more rapid tumor growth and a high rate of metastasis in vivo (18)
. As a means to compare the two methods for detection of differentially expressed mRNAs, Northern blot analysis was used to confirm differential expression of candidates identified by DD, and cDNAs of these differentially expressed genes were included in cDNA microarrays for validation (Fig. 1)
.
|
(left panel). These included bands detected (a) mostly in primary or transformed keratinocytes, and which exhibited a decrease in expression with tumor progression and metastasis; (b) mostly in PAM 212 cells; (c) in all tumor lines; (d) in metastatic lines only; and (e) in primary keratinocyte and metastatic lines. The percentage in each category are shown in Fig. 2
(right panel). The major differences in cDNA fragments detected were seen between primary keratinocytes and the five tumor lines, which comprised 76.8% of all cDNA candidates identified, and 75 (16.1%) of the cDNA fragments were detected uniquely in metastatic lines. The three fragments (0.7%) detected in both primary keratinocytes and metastatic lines and those expressed only in one or two LY or LU lines (not shown) were not considered for additional study.
|
shows the images of all nonredundant positive blots obtained in the study. All expression patterns showed consistency with DD experiments except band G1, which appeared in metastatic lines by DD but was detected in all tumor lines by Northern analysis. To control for loading, all blots used were reprobed with 32P-labeled cDNA fragment of glyceraldehyde-3-phosphate dehydrogenase and showed similar intensity of the signals (Fig. 3
, lower panels).
|
, the known genes identified by DD are underlined and classified according to their expression pattern with tumor progression and putative function as reported in previous studies. DD and Northern analysis revealed increased expression of candidates associated with inflammation and immune function (e.g., chemokine growth-regulated oncogene 1 [also called KC]; a proteasome component involved in antigen processing, LMP7, and lymphocyte antigen 6 [24, 25, 26, 27
]); signal transduction and transcription (c-Met, HGM-I, Rap 1b, and Yes-associated protein 65; Refs. 28, 29, 30, 31
); growth and apoptosis (gas5 and Nedd-8; Refs. 32
, 33
); adhesion/migration (ADAMTS-1; Ref. 34
); metabolism and drug resistance (e.g., glutathione S-transferase; Ref. 35
) and structure (e.g., Capping protein; Ref. 36
). Of the 24 unique genes, 8 showed increased expression in the metastatic lines, including Gro-1, c-Met, LMP-7, gas5, capping protein, spermidine synthase (a pseudogene), methlmalonyl-CoA mutase, sperm protein p179, and novel clone O34. The four candidates selected that exhibited decreased expression (thymosin ß4, actin- and spectrin-binding proteins, and tropomyosin 
) primarily have been associated with functions involved in cell structure and motility.
|
, as described in "Materials and Methods." The 57 cDNAs detected by both DD and Northern blot were included as a measure of validation. A cluster analysis of 287 genes that showed a >2-fold difference in intensity is shown in Fig. 4
. At least five gene expression patterns were detected and can be discerned as clusters, according to the relative levels of mRNA gene expression in each cluster. Genes in cluster 1, keratinocytes >> PAM 212 and LY, and cluster 2, keratinocytes > PAM 212 > LY, exhibited a decrease in expression with transformation and metastasis; genes in cluster 3, keratinocytes < PAM 212 > LY, cluster 4, keratinocytes < PAM 212 and LY, and cluster 5, keratinocytes < PAM 212 < LY, exhibited increased expression in tumor cells. Thus, among the five clusters, the majority of differences in gene expression were found to reside between keratinocytes and tumor lines, consistent with the results by DD (Fig. 2)
. The results using both methods demonstrated apparent differences in expression profiles that were associated with the stepwise changes observed in the phenotypic behavior of the cell lines after transformation in vitro and acquisition of a metastatic phenotype in vivo.
|
shows that 26 of 39 (66.7%) clones exhibiting differential expression by DD were detected by microarray. When compared with Northern blot, differential expression of 20 of 26 (76.9%) genes was detected by both methods, with 6 each detected by one method but not the other (Fig. 5B)
. Because two clones represented the same genes, there were 24 unique genes included. Microarray analysis was also used to compare mRNA from tumor cells grown in vitro and in vivo to obtain an estimate of differences in mRNA between cell lines and heterogeneous tumor tissue. We compared expression of mRNA detected in PAM 212 and LY cell lines grown in vitro and tumors established from PAM 212 and LY in mice (PAM 212*, LY-1*, and LY-2*), as shown in Figs. 4
5
6
. We observed a >50% concordant pattern of gene expression overall between in vitro and in vivo samples in cluster analysis (Fig. 5A)
. For genes detected by DD and Northern blot, Fig. 5A
shows an 70% concordance in the pattern of expression detected in Pam 212 and LY cell lines and Pam 212* and LY* tumors. These results comparing expression among cell lines and tumor tissue provide evidence for differences in the pattern of gene expression between cultured tumor cells in vitro and tumor and host cells in vivo.
|
|
without underlining. The cDNA microarrays enriched for cancer-associated genes detected differences in the expression of multiple genes with diverse functions. The differential pattern of expression and function of several of the candidates detected by cDNA microarray are consistent with those reported for various cancers. For example, decreased expression of growth-modulatory cell cycle-dependent kinase inhibitors cdk inhibitor 1A p21 (CIP1/WAF1) and cdk 4 inhibitor p27 (KIP1) and increased expression of cyclin D1, cdc 25, and PCNA have been implicated frequently in the proliferation of various cancers, including SCC (37, 38, 39, 40)
. Increased expression of genes involved in signal transduction and transcription, including the protein tyrosine phosphatase, Myc-associated zinc finger protein, Janus kinase 3, and E2F pathways, and decreased expression of syk have also been reported (41, 42, 43, 44, 45, 46)
. Increased expression of PDGF- and FasL has also been detected in SCC (47
, 48) . The pattern of expression and function of these candidates and others not well studied in SCC remains to be confirmed in this model and a wider panel of SCCs.
Metastasis-associated Genes Exhibit Diverse Functions and Include Multiple Genes Related to the NF-B Signal Pathway.
We examined further the cluster of genes exhibiting increased expression in metastatic lines and tumors, and the pattern of expression and identity of these genes is shown in Fig. 6
. Thirty-four genes were detected in this group, and three included in duplicate for quality assurance appeared twice. Among these genes, 22 are known genes, 1 is a putative gene, and 8 are ESTs. The known genes include candidates with a wide range of putative functions, and several have been shown previously to be expressed in various cancers including SCC. The greatest expression was detected in metastasis for several genes that function in immunological, inflammatory, and angiogenesis responses, including Gro-1 (KC; Refs. 24
and 25
), complement component 3 (49)
, IL-12B (50)
, CSF-1 (51
, 52)
, and OPN (53, 54, 55)
. Several candidates involved in signal transduction and regulation of gene expression and DNA replication were detected, including c-Met (56)
, neurotrophic receptor tyrosine kinase (57)
, HMG-1(Y) (29)
, and replication protein A (Mr 14,000 subunit; Ref. 58
). Three candidates detected have been reported to be expressed and involved in the modulation of apoptosis in cancer: cIAP-1 encodes a cellular inhibitor for caspase 3 (59
, 60)
; FasL encodes a membrane protein that activates a TNF family receptor that contains a death-domain (48
, 61)
; and PEA-15 encodes a recently cloned Mr 15,000 death effector domain-containing protein (62)
. Capping protein 2 encodes an actin-binding protein that may be involved in cell shape and mobility (36)
.
Recently, we demonstrated that increased levels of the Gro-1 (KC) and other cytokines detected in metastatic Pam LY and LU lines is attributable to increased activation of transcription factor NF-B (21)
. We analyzed whether gene expression in the metastasis cluster includes an enriched representation for other NF-B-related genes by a search of PubMed. Among the 22 known genes, 10 have been reported to be associated with the NF-B signal pathway (Fig. 6
, right column, solid lines and their association,). The 10 NF-B-related genes identified may be classified into two groups. One group includes candidates involved in the regulation of NF-B activation. For example, OPN encodes a secreted phosphoprotein that can promote the activation of NF-B by binding to integrins (63
, 64)
. HMG-1(Y) is required for NF-B-dependent induction of Gro-1 (29)
. Protein tyrosine phosphatase has been reported to modulate NF-B by interacting with IB (65)
. Ubiquitin-activating enzyme E1 participates in protein ubiquitination of IB proteins involved in the activation of NF-B (66
, 67)
. The second group includes NF-B target genes, such as Gro-1/KC, complement component 3, CSF-1, IL-12B, cIAP-1, and FasL. All of these have been shown to be genes regulated by NF-B in various cell types (21
, 49, 50, 51, 52
, 59, 60, 61)
. Thus, the cDNA array results are consistent with the enriched expression of NF-B-related genes in metastatic SCC lines that exhibit increased activation of NF-B.
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. Clusters of differentially expressed mRNAs associated with these stages were detected by both the random primer-based DD method and arrays containing a large number of genes associated with oncogenesis (Fig. 2
and 4
). The majority of DD candidates confirmed by Northern analysis (Fig. 3)
and included in the microarray for comparison were also detected by microarray (Fig. 5)
. The candidates detected by both methods included novel ESTs and known genes that function in inflammation/immunity, angiogenesis, cell growth and death, signal transduction, metabolism, and cell structure (Table 1)
. We identified a small group of 26 metastasis-related genes representing 11–16% of all differentially expressed genes identified in the current study (Fig. 6)
. Among these, 10 of 22 known genes are related to the NF-B signal transduction pathway. We have examined the functional importance of NF-B and the NF-B-inducible gene Gro-1/KC while these gene discovery studies were in progress. We found increased Gro-1 (KC) mRNA and protein expression in the metastases, and we found that Gro-1 (KC) promotes inflammation, angiogenesis, increased tumor growth, and metastasis after enforced expression in the low Gro-1 (KC)-expressing parental PAM 212 SCC in vivo (25)
. Conversely, inhibition of NF-B resulted in inhibition of proangiogenic chemokine expression, angiogenesis, and tumor growth of Pam LY-2 (68)
and human UM-SCC-9 cells (9)
. These results provide evidence for the functional importance of the NF-B signal pathway and NF-B induced gene(s) detected by DD and cDNA microarray in this study. The development of DD and microarray technology has enabled the study of global expression profiles of random or disease-associated genes. The combination of DD and microarray used in the current study allowed the detection of 30–50% of the total genes that are estimated to be differentially expressed in a given cell type (69 , 70) . In comparing 32 cDNA clones detected by DD, Northern blot, and cDNA array analyses, a 76.9% overlap was obtained. When we reviewed the expression of mRNAs detected by the 12 cDNA clones that showed a discrepancy, all were found to be of relatively low abundance when compared with other positive clones. The low expression levels of these genes either fell into the nonlinear detection range on the array, and failed to pass the filtering process, or were excluded during clustering analysis. We take these results as evidence that the fluorescence dye-based microarray and cluster analysis methods used in the current study may be slightly less sensitive than the PCR-based DD method in detection of low-abundance mRNA species in complex murine and human genomes.
To obtain an estimate of differences in mRNA expression that would be detected in cells in culture and in whole tumors, we included mRNA from Pam 212 and LY cell lines and tumors in microarray analysis (Fig. 4
5
6
). We observed a >50% concordant pattern of gene expression overall between in vitro and in vivo samples in cluster analysis (Fig. 5A)
and >70% concordance in genes confirmed by DD and Northern analysis (Fig. 5A)
. Although these results provide evidence that changes observed in cultured cell lines can also be detected in specimens obtained from whole tumors in vivo, they also indicate that there are important differences in expression in mRNA from tumors. Such differences could arise because of the presence of a variety of stromal cells, or because of inducible responses in tumor cells arising from interactions of tumor cells with the host environment. The advent of laser microdissection and other technologies can facilitate future studies to examine which of these differences are attributable to heterogeneity in tumor or stromal cells and activation of genes after exposure of tumor cells to the host environment (71
, 72)
.
Among the genes detected using both DD and microarray methods, only a relatively small number of candidate genes identified were found to be related to metastasis (30–50 genes). The detection of a finite number of candidates whose expression and function can be systematically studied underscores the potential usefulness of genomic approaches such as DD and cDNA microarray in the study of gene expression in tumor progression. The number and potential functional relatedness of the candidates detected in this study are consistent with recent results of Clark et al. (73) , whose genomic analysis in murine B16F0 melanoma lung metastasis and human melanotic tumor A375 also detected a relatively small number of candidates and a statistical association between genes detected with tumor progression.
The detection of the differential expression of genes involved in modulation of the NF-B signal transduction pathway is consistent with our hypothesis and previous experimental data indicating that constitutive activation of NF-B signal transduction pathway is important in the tumor progression and metastasis of SCC (8
, 9
, 68)
. Here we found evidence that increased activation of the NF-B pathway in metastatic SCC cells is accompanied by the altered expression of several genes that can regulate NF-B responses. In this group, ubiquitin-activating enzyme E1 participates in the initial steps of protein ubiquitination necessary for degradation of IB, an inhibitor of NF-B activation (66
, 67)
. Nedd-8 is another ubiquitin-like protein that can be activated by ubiquitin-activating enzyme E1 (74)
, functioning in modification of the Cul-1 component in a specific Skp1, Cdc53 or Cullin, and F-box complex, SCFßTrCP, a ubiquitin-ligase enzyme complex which carries out IB ubiquitination (33)
. Protein tyrosine phosphatase 1B has been speculated to modulate NF-B by physically interacting with IB, resulting in dephosphorylation of tyrosine in IB (75)
. LMP-7 is a component of the 26S proteasome that participates in the final stage of degradation of IB proteins and antigen processing (26)
. HMG-I(Y) was originally identified as a basic, nonhistone, chromosomal binding protein that regulates gene expression by relieving histone H1-mediated transcriptional repression and is required for NF-B-dependent induction of cytokines Gro-1 (KC), and granulocyte macrophage CSF (29
, 76)
, which are overexpressed in metastatic PAM cells (20)
. Taken together, ubiquitin-activating enzyme E1, Nedd-8, protein tyrosine phosphatase 1B, and LMP-7 are involved in degradation of IB and NF-B activation, and HMG-I(Y) acts as functional enhancer for NF-B transcription activity.
In addition to genes that are related to NF-B signal pathway, differential expression of components involved in several other signal transduction pathways were identified in transformed or metastatic PAM cells. We detected altered expression of the hepatocyte growth factor/scatter factor receptor c-Met, epidermal growth factor receptor and Ras-associated kinase Rap-1b, PDGF- and the PDGF receptor-associated Yes-associated protein (YAP65), neurotrophic receptor tyrosine kinase, protein tyrosine phosphatase 1B, and syk. The expression patterns of several of these candidates are consistent with alterations detected in other cancers. Activation or elevated expression of c-Met receptor, EGF-R, and PDGF receptor pathway genes have been detected and shown to be important in tumor cell proliferation, survival, angiogenesis and/or metastasis of SCC (28
, 56
, 77, 78, 79, 80, 81)
. We have completed studies confirming expression and function of the EGF, c-Met, and PDGF receptors and their ligands in PAM 212 and/or human SCC cell lines.4
,5
,6
We found that activation of epidermal growth factor receptor and c-Met induced expression of angiogenesis factors IL-8 and VEGF in human HNSCC tumor cells.4
,5
Expression of neurotrophic receptor has been reported in thyroid papillary carcinoma (82)
, and decreased expression of syk has been reported in breast cancer (46)
. The relative importance of the altered expression of the genes involved in these other pathways to the malignant phenotype of PAM and other SCC remains to be determined.
We detected altered expression of several genes involved in inflammation and angiogenesis in transformed and metastatic SCC, including Gro-1 (KC), ADAMTS-1, and OPN. In addition to the direct evidence already obtained regarding the role of Gro-1 (KC) in angiogenesis, growth, and metastasis in the Pam model, ADAMTS-1 and OPN are attractive candidates. In contrast to Gro-1, ADAMTS-1 expression was decreased in all three metastatic cell lines. ADAMTS-1 is a mouse metalloproteinase and disintegrase with thrombospondin motifs. Its human ortholog, METH-1, was identified as a member of a new family proteins with antiangiogenic activity (83, 84, 85)
. OPN is a phosphoprotein expressed in primary and metastatic carcinomas, including SCC, and has been reported to promote endothelial survival through binding to integrin vß3 and activation of NF-B in a ras- and src-dependent manner (53, 54, 55
, 63
, 64)
. OPN is a strong stimulator for endothelial cell migration and is functionally synergistic with VEGF (64)
. Taken together, our experimental data provide evidence that differences in expression of multiple genes that can modulate angiogenesis accompany tumor progression and metastasis of SCC.
Several differentially expressed genes that we identified regulate cell growth and apoptosis and are critically altered in tumor development and progression. Cell cycle-dependent kinase inhibitors cdk inhibitor 1A p21 (CIP1/WAF1) and cdk 4 inhibitor p27 (KIP1) have been reported to be down-regulated, and cyclin D1, cdc 25, and PCNA have been shown to be up-regulated and involved in the proliferation of various cancers (37, 39, 40)
. cIAP-1, FasL, PEA-15, and Nedd-8 genes are involved in modulating apoptosis. cIAP-1, which exhibits increased expression in Pam and LY SCC cells, has been shown to mediate the NF-B-mediated resistance of cancer cells to apoptosis, including that induced by TNF, FasL, cytotoxic chemotherapy agents, and radiation (11, 12, 13)
. cIAP-1 is a potent inhibitor of cell death proteases, especially caspase-3 and 7, thereby inhibiting apoptosis in tumor cells (59
, 60)
. The expression pattern of cIAP-1 observed is consistent with our observations in murine and human SCC that increased resistance to TNF and radiation-induced apoptosis accompanies activation of NF-B during tumor progression and metastasis (86
, 87)
.6
Increased expression of PEA-15 in tumor cells has been shown to mediate increased resistance to Fas as well as TNF-induced apoptosis in tumor cells by inhibiting caspase 8 activity (62)
. Increased FasL and decreased Fas expression have been detected in human HNSCC, and such altered gene expression reportedly promotes the resistance of tumor cells to FasL-mediated apoptosis while inducing apoptosis and suppression of T cell-mediated immunity (48)
.
In conclusion, using genomic approaches, we have detected global alterations in the expression profile of genes associated with transformation and metastatic tumor progression in a murine SCC model and obtained evidence that these changes involve NF-B and potentially other signal pathways. Activation of these signal transduction pathways is associated with an altered expression of genes involved in angiogenesis, growth, and apoptosis, which can contribute to a more aggressive malignant phenotype, including metastasis. Examination of the function of several of the preferentially expressed genes identified from this study are underway in both animal tumor models and in human HNSCC, and this information may be useful in molecular diagnosis, selection, and targeting of therapy.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by National Institute on Deafness and Other Communication Disorders Intramural Project DC-00016. 
2 To whom requests for reprints should be addressed, at Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders/NIH, Building 10, Room 5D55, Bethesda, MD 20892.
3 The abbreviations used are: SCC, squamous cell carcinomas; NF-B, nuclear factor-B; AP-1, activator protein-1; DD, differential display; Gro-1, chemokine growth-regulated oncogene 1; cdk, cyclin-dependent kinase; OPN, osteopontin; FasL, Fas ligand; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; HNSCC, head and neck squamous cell carcinoma; CSF, colony-stimulating factor; EST, expressed sequence tag; IL, interleukin.
4 G. Dong, Z. Chen, Z. Y. Li, N. T. Yeh, C. C. Bancroft, and C. Van Waes. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K pathways contributes to expression of proangiogenic cytokines IL-8, and VEGF in head, and neck squamous cell carcinoma, submitted for publication.
5 C. C. Bancroft, U. Yeh, Z. Chen, U. B. Sunwoo, G. Dong, C. Park, N. Yeh, S. Jackson, and C. Van Waes. Epidermal growth factor receptor coactivates the NF-B and AP-1 signal pathways and expression of angiogenesis factors IL-8 and VEGF in human head and neck squamous cell carcinoma lines, manuscript submitted.
Received 1/23/01. Accepted 4/12/01.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst., 90: 824-832, 1998.6 ß4. Cancer Res., 51: 2395-2402, 1991., IL-1RA and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines. Cancer Res., 58: 3668-3676, 1998.B in a human head and neck squamous cell carcinoma inhibits NF-B, proinflammatory cytokine expression and tumor growth in vivo. Cancer Res., 59: 3468-3474, 1999.B transcription factors. Oncogene, 18: 6910-6924, 1999.[Medline]
B: control of oncogenesis and cancer therapy resistance. Biochim. Biophys. Acta., 1470: M55-M62, 2000.[Medline]
B and activator protein-1 activation block the neoplastic transformation response. Cancer Res., 57: 3569-3576, 1997.B transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene, 16: 2711-2722, 1998.[Medline]
, IL-6, GM-CSF and KC. Clin. Exp. Metastasis, 16: 655-664, 1998.[Medline]
B and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res., 59: 3954-3504, 1999.-granule proteins. J. Biol. Chem., 264: 4133-4137, 1989.B regulate transcription of the MGSA/GRO gene. Nucleic Acids Res., 23: 4210-4219, 1995.B. Mol. Cell. Biol., 20: 2326-2333, 2000. subunit genes and pseudogenes. Genomics, 39: 264-270, 1997.[Medline]
B inhibitors and by transfection with ser 32/36 mutant IB. J. Surg. Res., 82: 48-55, 1999.[Medline]
B. Cell. Immunol., 199: 50-57, 2000.[Medline]
and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J. Leukoc. Biol., 68: 495-502, 2000.. Mol. Cell, 5: 617-627, 2000.[Medline]
B and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells. J. Biol. Chem., 275: 10023-10029, 2000.B mediated vß3 integrin-induced endothelial cell survival. J. Cell Biol., 141: 1083-1093, 1998.B by a novel ubiqutination-dependent protein kinase activity. Cell, 84: 853-862, 1996.[Medline]
B, cell survival, tumor growth and angiogenesis in squamous cell carcinoma. Clin. Cancer Res., 7: 1419-1428, 2001.B through interaction between the PDZ1 domain and ankyrin repeats. Biochem. J., 337: 179-184, 1999.
B by a mutant inhibitor-B attenuates resistance of human head and neck squamous cell carcinoma to TNF- caspase-mediated cell death. Br. J. Cancer, 83: 1367-1374, 2000.[Medline]
B in head and neck squamous carcinomas. Head Neck, 22: 748-759, 2000.[Medline]
This article has been cited by other articles:
|
|
 |
|
  C. Bartholomeusz, D. Rosen, C. Wei, A. Kazansky, F. Yamasaki, T. Takahashi, H. Itamochi, S. Kondo, J. Liu, and N. T. Ueno PEA-15 Induces Autophagy in Human Ovarian Cancer Cells and Is Associated with Prolonged Overall Survival Cancer Res., November 15, 2008; 68(22): 9302 - 9310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Wang, N. Cao, D. Nantajit, M. Fan, Y. Liu, and J. J. Li Mitogen-activated Protein Kinase Phosphatase-1 Represses c-Jun NH2-terminal Kinase-mediated Apoptosis via NF-{kappa}B Regulation J. Biol. Chem., July 25, 2008; 283(30): 21011 - 21023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Lee, X. P. Yang, B. Yan, J. Friedman, P. Duggal, L. Bagain, G. Dong, N. T. Yeh, J. Wang, J. Zhou, et al. A Novel Nuclear Factor-{kappa}B Gene Signature Is Differentially Expressed in Head and Neck Squamous Cell Carcinomas in Association with TP53 Status Clin. Cancer Res., October 1, 2007; 13(19): 5680 - 5691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Van Waes, M. Yu, L. Nottingham, and M. Karin Inhibitor-{kappa}B Kinase in Tumor Promotion and Suppression During Progression of Squamous Cell Carcinoma Clin. Cancer Res., September 1, 2007; 13(17): 4956 - 4959. [Full Text] [PDF]
|
|
|
|
|
|
W. L. Bigbee, J. R. Grandis, and J. M. Siegfried Multiple Cytokine and Growth Factor Serum Biomarkers Predict Therapeutic Response and Survival in Advanced-Stage Head and Neck Cancer Patients Clin. Cancer Res., June 1, 2007; 13(11): 3107 - 3108. [Full Text] [PDF]
|
|
|
|
|
|
A. Perfetti, F. Oriente, S. Iovino, A. T. Alberobello, A. P. M. Barbagallo, I. Esposito, F. Fiory, R. Teperino, P. Ungaro, C. Miele, et al. Phorbol Esters Induce Intracellular Accumulation of the Anti-apoptotic Protein PED/PEA-15 by Preventing Ubiquitinylation and Proteasomal Degradation J. Biol. Chem., March 23, 2007; 282(12): 8648 - 8657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Brennan, Y. Hu, S. Joubeh, Y. W. Choi, D. Whitaker-Menezes, T. O'Brien, J. Uitto, U. Rodeck, and M. G. Mahoney Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes J. Cell Sci., March 1, 2007; 120(5): 758 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Glading, J. A. Koziol, J. Krueger, and M. H. Ginsberg PEA-15 Inhibits Tumor Cell Invasion by Binding to Extracellular Signal-Regulated Kinase 1/2 Cancer Res., February 15, 2007; 67(4): 1536 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Van Waes Nuclear Factor-{kappa}B in Development, Prevention, and Therapy of Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1076 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Renault-Mihara, F. Beuvon, X. Iturrioz, B. Canton, S. De Bouard, N. Leonard, S. Mouhamad, A. Sharif, J. W. Ramos, M.-P. Junier, et al. Phosphoprotein Enriched in Astrocytes-15 kDa Expression Inhibits Astrocyte Migration by a Protein Kinase C{delta}-dependent Mechanism Mol. Biol. Cell, December 1, 2006; 17(12): 5141 - 5152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Lee, R. F. Swaby, Y. Liang, S. Yu, S. Liu, K. H. Lu, R. C. Bast Jr., G. B. Mills, and X. Fang Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene {alpha} in Ovarian Cancer. Cancer Res., March 1, 2006; 66(5): 2740 - 2748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Stassi, M. Garofalo, M. Zerilli, L. Ricci-Vitiani, C. Zanca, M. Todaro, F. Aragona, G. Limite, G. Petrella, and G. Condorelli PED Mediates AKT-Dependent Chemoresistance in Human Breast Cancer Cells Cancer Res., August 1, 2005; 65(15): 6668 - 6675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Krueger, F.-L. Chou, A. Glading, E. Schaefer, and M. H. Ginsberg Phosphorylation of Phosphoprotein Enriched in Astrocytes (PEA-15) Regulates Extracellular Signal-regulated Kinase-dependent Transcription and Cell Proliferation Mol. Biol. Cell, August 1, 2005; 16(8): 3552 - 3561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Talbot, C. Estilo, E. Maghami, I. S. Sarkaria, D. K. Pham, P. O-charoenrat, N. D. Socci, I. Ngai, D. Carlson, R. Ghossein, et al. Gene Expression Profiling Allows Distinction between Primary and Metastatic Squamous Cell Carcinomas in the Lung Cancer Res., April 15, 2005; 65(8): 3063 - 3071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lun, P. L. Zhang, P. K. Pellitteri, A. Law, T. L. Kennedy, and R. E. Brown Nuclear Factor-kappaB Pathway as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma: Pharmaceutical and Molecular Validation in Human Cell Lines Using Velcade and siRNA/NF-{kappa}B. Ann. Clin. Lab. Sci., January 1, 2005; 35(3): 251 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Loercher, T. L. Lee, J. L. Ricker, A. Howard, J. Geoghegen, Z. Chen, J. B. Sunwoo, R. Sitcheran, E. Y. Chuang, J. B. Mitchell, et al. Nuclear Factor-{kappa}B is an Important Modulator of the Altered Gene Expression Profile and Malignant Phenotype in Squamous Cell Carcinoma Cancer Res., September 15, 2004; 64(18): 6511 - 6523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Petty, M. C. Nicolson, K. M. Kerr, E. Collie-Duguid, and G. I. Murray Gene Expression Profiling in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application Clin. Cancer Res., May 15, 2004; 10(10): 3237 - 3248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Schmalbach, D. B. Chepeha, T. J. Giordano, M. A. Rubin, T. N. Teknos, C. R. Bradford, G. T. Wolf, R. Kuick, D. E. Misek, D. K. Trask, et al. Molecular Profiling and the Identification of Genes Associated With Metastatic Oral Cavity/Pharynx Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, March 1, 2004; 130(3): 295 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fukuchi, M. Date, Y. Azuma, M. Shinohara, H. Takahashi, and K. Ohura Apoptosis in Human Oral Squamous Cell Carcinomas is Induced by 15-Deoxy-{Delta}12,14-Prostaglandin J2 but not by Troglitazone Journal of Dental Research, October 1, 2003; 82(10): 802 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, L. Duke, P. S. Zhang, R. B. Arlinghaus, W. F. Symmans, A. Sahin, R. Mendez, and J. L. Dai Alternative Splicing Disrupts a Nuclear Localization Signal in Spleen Tyrosine Kinase That Is Required for Invasion Suppression in Breast Cancer Cancer Res., August 1, 2003; 63(15): 4724 - 4730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Gonzalez, M. Gujrati, M. Frederick, Y. Henderson, J. Arumugam, P. W. Spring, K. Mitsudo, H.-W. Kim, and G. L. Clayman Identification of 9 Genes Differentially Expressed in Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, July 1, 2003; 129(7): 754 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kakiuchi, Y. Daigo, T. Tsunoda, S. Yano, S. Sone, and Y. Nakamura Genome-Wide Analysis of Organ-Preferential Metastasis of Human Small Cell Lung Cancer in Mice Mol. Cancer Res., May 1, 2003; 1(7): 485 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, J. B. Wyckoff, V. C. Frohlich, Y. Oleynikov, S. Huttelmaier, J. Zavadil, L. Cermak, E. P. Bottinger, R. H. Singer, J. G. White, et al. Single Cell Behavior in Metastatic Primary Mammary Tumors Correlated with Gene Expression Patterns Revealed by Molecular Profiling Cancer Res., November 1, 2002; 62(21): 6278 - 6288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Lian, Y. Kluger, D. S. Greenbaum, D. Tuck, M. Gerstein, N. Berliner, S. M. Weissman, and P. E. Newburger Genomic and proteomic analysis of the myeloid differentiation program: global analysis of gene expression during induced differentiation in the MPRO cell line Blood, October 16, 2002; 100(9): 3209 - 3220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Hamadeh, K. J. Trouba, R. P. Amin, C. A. Afshari, and D. Germolec Coordination of Altered DNA Repair and Damage Pathways in Arsenite-Exposed Keratinocytes Toxicol. Sci., October 1, 2002; 69(2): 306 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nie, J. Liao, X. Zhao, Y. Song, G.-y. Yang, L.-D. Wang, and C. S. Yang Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma Carcinogenesis, October 1, 2002; 23(10): 1713 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Imoto, H. Tsuda, A. Hirasawa, M. Miura, M. Sakamoto, S. Hirohashi, and J. Inazawa Expression of cIAP1, a Target for 11q22 Amplification, Correlates with Resistance of Cervical Cancers to Radiotherapy Cancer Res., September 1, 2002; 62(17): 4860 - 4866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Caamano and C. A. Hunter NF-{kappa}B Family of Transcription Factors: Central Regulators of Innate and Adaptive Immune Functions Clin. Microbiol. Rev., July 1, 2002; 15(3): 414 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chen, A. Fribley, and C.-Y. Wang Potentiation of Tumor Necrosis Factor-mediated Apoptosis of Oral Squamous Cell Carcinoma Cells by Adenovirus-mediated Gene Transfer of NF-{kappa}B Inhibitor Journal of Dental Research, February 1, 2002; 81(2): 98 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Julian Preston Quantitation of Molecular Endpoints for the Dose-Response Component of Cancer Risk Assessment Toxicol Pathol, January 1, 2002; 30(1): 112 - 116. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
